Latest Drugs, Latest Approval in Protease-activated receptor-1 antagonists

What are Protease-activated receptor-1 antagonists?

Protease-activated receptor-1 (PAR 1) antagonists have an antiplatelet effect by inhibiting thrombin-related platelet aggregation.

Thrombin's cellular effects are mediated by PARs therefore the action of the PAR 1 antagonists alters signalling in platelets and interferes with platelet activation.

PAR 1 antagonists are used to reduce the risk of thrombotic cardiovascular events in patients who have an increased risk of myocardial infarction or peripheral arterial disease.